Companies that trade on major exchanges have a far better chance of receiving coverage from independent research firms and investment banks, which will ultimately help drive market and investment activity in a particular stock. Most independent research firms and investment banks however do not provide coverage for companies trading on the OTC markets.
PetVivo, Inc. (OTCQB: PETV), is the producer of “Kush”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses is intended to provide a lubricious cushion between the bones to reinforce cartilage. KUSH is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.
Petvivo currently has 17 products in its pipeline with its feature product being “Kush”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses is intended to provide a lubricious cushion between the bones to reinforce cartilage.
On Friday, shares broke resistance on record dollar volume which makes perfect sense as there are over 2 million equine owners in the US, many of which pay attention to this convention.
Should it be a surprise that we learned just last week in the company’s 8-K that PetVivo Holdings, Inc. (OTCQB: PETV) adopted and approved an amended and restated “Charter of the Audit Committee”, “Charter of the Compensation Committee” and a “Nominating and Corporate Governance Committee Charter?” All of which are required by NASDAQ.
There is a niche biotech company called PetVivo, Holdings, Inc. (OTCQB: PETV). They are an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets. PetVivo is benefiting from trials on the human side with a lower barrier to approval for pets.
Have a look at PetVivo Holdings, Inc. (OTCQB: PETV). The stock has recently moved from a low of about $.20 per share up to over $1.60 on increasing volume.
On August 14, Pet Vivo Holdings, Inc. (OTCQB: PETV) filed its quarterly report for the period ending June 30, 2020. In it, it showed current liabilities of $2.14 million. Since then, the company settled over $600,000.00 in liabilities which is reflected in recent 8K “material event” filings, as well as in its next quarterly report.
Back in July, the stock was given a target price of between $1.74 and $2.32 per share by Marble Arch Research. You can download the full report here: - Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”